Rappaport Family Institute for Research in the Medical Sciences

Technion Research & Development Foundation Ltd

Rapport Family Institute for Research in the Medical Sciences

Rappaport Family Institute for Research in the Medical Services

Nathan Karin

Gizi Wildbaum

Yaniv Zohar

Nir Netzer

Rachel Anunu

Yiftah Barsheshet

Uri Weinberg

Sawsan Youssef

Liat Izhak

The present invention relates to a peptide comprising an epitope within the macrophage scavenger receptor B-I, a method of using the same, a nucleic acid encoding the same and an antibody that binds to the epitope.

Epitope as a target for therapy of inflammatory autoimmune diseases and graft rejection

A method of treating a medical condition in which suppression of effector T cells is beneficial in a subject in need thereof is disclosed. The method comprising administering to the subject a therapeutically effective amount of a CCL1 polypeptide, thereby treating the medical condition in the subject.

Use of CCL1 in therapy

A method of treating multiple sclerosis (MS) in a subject in need thereof, the method comprising administering to said subject a therapeutically effective amount of an isolated polypeptide comprising an antigen recognition domain capable of specifically binding a human scavenger receptor, wherein said antigen recognition domain comprises CDR amino acid sequences as set forth in SEQ ID NO: 11, 15, 19, 23, 27 and 31, thereby treating MS in the subject.

Compositions and methods for diagnosing and treating an inflammation

A method of reducing an inflammatory response in a subject is provided. The method comprising providing to a subject in need thereof a therapeutically effective amount of an agent capable of reducing activity and/or expression of a scavenger receptor or of an effector thereof, thereby reducing the inflammatory response in the subject.

A method of treating a graft rejection disease in a subject in need thereof, the method comprising administering to said subject a therapeutically effective amount of an isolated polypeptide comprising an antigen recognition domain capable of specifically binding a human scavenger receptor, wherein said antigen recognition domain comprises CDR amino acid sequences as set forth in SEQ ID NO: 11, 15, 19, 23, 27 and 31, thereby treating the graft rejection disease in the subject.

An isolated polypeptide is provided. The polypeptide comprising an antigen recognition domain capable of specifically binding a human scavenger receptor, wherein the antigen recognition domain comprises at least three CDR amino acid sequences selected from the group consisting of SEQ ID NO: 11, 15, 19, 23, 27 and 31. Also provided are compositions which comprise the peptide and uses of same.

A method of diagnosing and determining a predisposition to prostate cancer is provided. The method comprising determining levels of MCP-1 antibodies and PSA in a sample of a subject and comparing to the level in healthy male controls, thereby diagnosing and determining a predisposition to the prostate cancer in the subject.

Compositions and methods for diagnosing and treating prostate cancer

Molecules and compositions including same for the isolation of MCP-1 and treatment of CCR2/MCP-1 associated diseases.

Molecules and methods of using same for treating MCP-1/CCR2 associated diseases

A method of treating an autoimmune disease such as Multiple Sclerosis is disclosed. The method comprises administering to a subject a therapeutically effective amount of CXCL11. Polypeptides and pharmaceutical compositions for treating same are also disclosed.

Growing community of inventors

Haifa, Israel

Nathan Karin